The United Laboratories International Holdings Limited
聯邦制藥國際控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3933)

UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDY FOR OVERWEIGHT OR OBESITY IN CHINA

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the first participant has been dosed in the Phase III clinical trial in China for overweight or obesity (the "Study") of UBT251 Injection, a Class 1 innovative drug self-developed by The United Bio-Technology (Hengqing) Co., Ltd. ("United Biotechnology"), a wholly-owned subsidiary of the Company.

The Study adopts a randomized, double-blind, parallel, placebo-controlled trial design and is planned to enroll 600 participants with obesity (BMI≥28.0 kg/m²) or overweight (24.0 kg/m²≤ BMI< 28.0 kg/m²) accompanied by at least one weight-related comorbidity. The Study is intended to evaluate the efficacy and safety of UBT251 Injection in participants with overweight or obesity. The primary endpoints are the percentage change in body weight from baseline and the proportion of participants achieving a weight reduction ≥5% from baseline after 52 weeks of treatment.

ABOUT UBT251

UBT251 is a long-acting triple-target receptor agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon). To date, the Company has been approved to conduct clinical trials in China and/or the United States for multiple indications including type 2 diabetes in adults, overweight or obesity, chronic kidney disease ("CKD"), metabolic dysfunction-associated steatohepatitis ("MASH") and moderate-to-severe obstructive sleep apnea ("OSA") with obesity. The Company is the first enterprise in China and the second globally to be approved for clinical trials of a long-acting triple agonist of GLP-1R/GIPR/GCGR prepared by chemical synthesis of polypeptide.

In March 2025, United Biotechnology and the Company entered an exclusive license agreement with Novo Nordisk A/S for UBT251.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 4 September 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.